PACAP38 Induced Headache, Migraine and Flushing in Patients With Migraine
Status:
Completed
Trial end date:
2019-12-07
Target enrollment:
Participant gender:
Summary
The aim is to investigate the incidence of headache, migraine attacks and flushing after
pituitary adenylate cyclase-activating peptide-38 (PACAP38) with and without treatment with
sumatriptan in patients with migraine